22 records found.
Apr 01, 2019
TCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Mar 28, 2019
TCR2 Therapeutics Presents Preclinical Data on its Lead Solid Tumor and Blood Cancer Programs at the American Association for Cancer Research (AACR) Annual Meeting
Mar 26, 2019
TCR2 Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult for the Manufacturing of its Novel T Cell Therapies for Cancer
Feb 26, 2019
TCR2 Therapeutics Announces Exercise of Over-Allotment Option
Feb 13, 2019
TCR2 Therapeutics Announces Pricing of Initial Public Offering of Common Stock
Feb 01, 2019
TCR2 Therapeutics Launches Proposed Initial Public Offering
Dec 19, 2018
TCR2 Therapeutics Announces Oncology Industry Leader and Expert Andrew Allen, M.D., Ph.D. Joins its Board of Directors
Nov 29, 2018
TCR2 Therapeutics wins U.S. Private Company of the Year Award at LifeStars Awards(TM) Life Sciences 2018 Event
May 14, 2018
TCR2 Therapeutics to Present at the UBS Global Healthcare Conference and the Jefferies 2018 Global Healthcare Conference
Apr 12, 2018
TCR2 Therapeutics to Present New Preclinical Data at the American Association for Cancer Research (AACR) 2018 Annual Meeting
Apr 10, 2018
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
Mar 06, 2018
TCR2 Therapeutics to Present at the Cowen and Company 38th Annual Healthcare Conference and Needham & Company 17th Annual Healthcare Conference
Feb 05, 2018
TCR2 Therapeutics to Present at the 2018 Keystone Symposia Conference on Emerging Cellular Therapies: T Cells and Beyond
Jan 03, 2018
TCR2 Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Nov 02, 2017
TCR2 Therapeutics Appoints Cell Therapy Pioneer Dr. Stephan Grupp to Advisory Board
Oct 31, 2017
TCR2 Therapeutics to Present New Data from its TRuC(TM) T Cell Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 11, 2017
TCR2 Therapeutics Appoints Leading Cell Therapy Expert as Chief Medical Officer
Sep 15, 2017
TCR2 Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology Frontiers
Aug 29, 2017
TCR2 Therapeutics to Present Solid Tumor Data at CAR-TCR Summit and CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Aug 08, 2017
TCR2 Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Pages